Citius Oncology, Inc. CTOR 深 沪
已收盘 07-02 16:00:00 美东时间
0.6804
-0.024
-3.39%
华盛通- 最 高0.7199
- 今 开0.6975
- 成交量 9801股
- 最 低 0.6612
- 昨 收 0.7043
- 总市值 6326.44万
- 52周最高 2.84
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.4912
- 委 比 -92.67%
- 总股本 9298.12万
- 历史最高 49.00
- 量 比 0.21
- 振 幅 8.33%
- 历史最低 0.00
- 每 手 1
- 风险率 0.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Citius Oncology Presents Phase 1 Clinical Data Of LYMPHIR In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies At American Society Of Clinical Oncology Annual Meeting
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today highlighted
06-01 19:21
Citius Oncology Provides Commercial Update On U.S. Launch Of LYMPHIR For Treatment Of CTCL, Highlighting Continued Adoption And Advancing Investigator-Led Clinical Studies
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integrationCRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius
03-31 21:14
美股夜盘 | Health In Tech, Inc. Class A涨50.00%，ZenaTech, Inc.涨19.30%
Health In Tech, Inc. Class A涨50.00%；ZenaTech, Inc.涨19.30%；金山云涨15.24%
03-18 15:03
Citius Oncology Announces Topline Results From Investigator‑Initiated Phase 1 Trial Of LYMPHIR Administered Prior To Commercial CD19‑Directed CAR‑T Therapy In High‑Risk DLBCL; Co Says LYMPHIR Was Well-Tolerated With No Dose-Limiting Toxicities Observed
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was
03-04 22:18
Earnings Breakdown: Citius Oncology Q1
Citius Oncology (NASDAQ:CTOR) reported its Q1 earnings results on Friday, Febru...
02-13 21:24
Citius Oncology Q1 Earnings Summary & Key Takeaways
The earnings results for Citius Oncology (NASDAQ:CTOR) for Q1 were made public ...
02-13 21:12
Citius Oncology Q1 EPS $(0.06) Misses $(0.04) Estimate, Sales $3.944M Miss $4.373M Estimate
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 50 percent. This is a 33.33 percent increase over losses of $(0.09) per share from
02-13 21:10
Citius Oncology Enters Distribution Agreement With Uniphar For LYMPHIR Distribution Into European Union
This agreement represents Citius Oncology's third international distribution partnership.Under the terms of the agreement, Uniphar will serve as the exclusive distribution partner for LYMPHIR in designated international
02-11 21:19
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
2025-09-24 10:23
Maxim Group Upgrades Citius Oncology to Buy, Announces $6 Price Target
Maxim Group analyst Michael Okunewitch upgrades Citius Oncology (NASDAQ:CTOR) from Hold to Buy and announces $6 price target.
2025-09-23 19:47
